Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1987 May;91(1):237-43.
doi: 10.1111/j.1476-5381.1987.tb09004.x.

Coexistence of carriers for dopamine and GABA uptake on a same nerve terminal in the rat brain

Coexistence of carriers for dopamine and GABA uptake on a same nerve terminal in the rat brain

G Bonanno et al. Br J Pharmacol. 1987 May.

Abstract

The ability of gamma-aminobutyric acid (GABA) to affect the release of [3H]-dopamine in rat brain synaptosomes prepared from corpus striatum, frontal cortex and hypothalamus and prelabelled with the radioactive catecholamine in the presence of desipramine was examined. GABA (10-300 microM) increased in a concentration-dependent way the basal release of [3H]-dopamine from striatum and cortical synaptosomes; however, its effect was much less pronounced in hypothalamic nerve terminals. 2,4-Diaminobutyric acid (DABA) mimicked GABA although less potently. Neutral amino acids such as leucine, valine or alpha-aminoisobutyric acid (100-300 microM) did not affect or increased minimally the release of [3H]-dopamine. The GABA-induced [3H]-dopamine release was not prevented by the GABAA-receptor antagonists, bicuculline or picrotoxin. The GABAA-receptor agonist, muscimol (10-300 microM), displayed only a very weak, not significant, enhancing effect on [3H]-dopamine release. The GABAB-receptor agonist (-)-baclofen (100 or 300 microM) had no effect. Three novel and selective inhibitors of GABA uptake, N-(4,4-diphenyl-3-butenyl)-nipecotic acid (SK&F 89976A), N-(4,4-diphenyl-3-butenyl)-guvacine (SK&F 100330A) and N-(4,4-diphenyl-3-butenyl)-homo-beta-proline (SK&F 100561) potently counteracted the enhancing effect of GABA on [3H]-dopamine release. Nipecotic acid also reduced the effect of GABA. It is concluded that carriers for the uptake of dopamine and GABA may coexist on the same nerve terminal in the rat brain.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Neurochem. 1966 Aug;13(8):655-69 - PubMed
    1. Proc R Soc Lond B Biol Sci. 1984 May 22;221(1224):245-60 - PubMed
    1. Eur J Pharmacol. 1974 Mar;25(3):411-4 - PubMed
    1. Anal Biochem. 1975 Mar;64(1):149-69 - PubMed
    1. Brain Res. 1976 Jan 16;101(2):341-4 - PubMed

Publication types

LinkOut - more resources